The challenge of cardiovascular risk factors in end-stage renal disease

J Nephrol. 2003 Jul-Aug;16(4):476-86.

Abstract

Due to the impressive cardiovascular (CV) morbidity and mortality in uremic patients, assessment of CV risk factors in the dialysis population is a crucial challenge in nephrology. Cardiovascular risk factors in dialysis patients may have a different significance in ESRD patients compared to the general population. The Framingham risk equation seems not to be valid in chronic uremia. Furthermore, new powerful outcome predictors have emerged in recent years: pulse pressure, dipping status, pulse wave velocity, augmentation index. The concept of "U"-shaped association between blood pressure (as well as cholesterolemia) and mortality are extensively discussed. The authors are focusing on the value of office and ambulatory blood pressure measurements in the uremic population. An extensive evaluation of blood pressure and vascular compliance in dialysis patients is proposed. Efficient dialysis, ACE-inhibitors and beta-blockers, statins, antiplatelet treatment and adequate control of calcium-phosphorus metabolism should be the mainstay of therapy in the ESRD patients with several CV risk factors.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure Determination
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology*
  • Comorbidity
  • Female
  • Humans
  • Hyperlipidemias / diagnosis
  • Hyperlipidemias / drug therapy
  • Hypertension / diagnosis
  • Hypertension / drug therapy
  • Hypertension / epidemiology*
  • Hypolipidemic Agents / therapeutic use
  • Incidence
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / epidemiology*
  • Male
  • Middle Aged
  • Prognosis
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods
  • Risk Factors
  • Sex Distribution
  • Smoking / adverse effects
  • Survival Analysis

Substances

  • Antihypertensive Agents
  • Hypolipidemic Agents